SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Teper Daniel Gedeon

(Last)

(First)

(Middle)

777 OLD SAW MILL RIVER RD.

(Street)

TARRYTOWN

10591

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUNE PHARMACEUTICALS INC [ EPCTD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2013

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/25/2013		A		4,260,556	A	⁽¹⁾	4,260,556	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.0424	08/25/2013		A		178,545		08/25/2013	07/09/2022	Common stock, par value $0.0001	178,545	⁽²⁾	178,545⁽³⁾	D
Stock Option (right to buy)	$0.7324	08/25/2013		A		29,758		08/25/2013	07/09/2022	Common stock, par value $0.0001	29,758	⁽⁴⁾	29,758⁽³⁾	D
Stock Option (right to buy)	$1.0286	08/25/2013		A		11,903		08/25/2013	02/28/2023	Common stock, par value $0.0001	11,903	⁽⁵⁾	11,903⁽³⁾	D

Explanation of Responses:

1. Received in exchange for 7,158,809 ordinary shares of Immune Pharmaceuticals Ltd. in connection with the merger between the issuer and Immune Pharmaceuticals Ltd. On the effective date of the merger, the most recent closing price of the issuers common stock on the OTCQX was $3.50 per share.

2. Received in the merger between the issuer and Immune Pharmaceuticals Ltd. in exchange for options to acquire 300,000 ordinary shares of Immune Pharmaceuticals Ltd. at an exercise price of 0.10 NIS or approximately $0.0278 per share.

3. Only represents the derivative securities of this class.

4. Received in the merger between the issuer and Immune Pharmaceuticals Ltd. in exchange for options to acquire 50,000 ordinary shares of Immune Pharmaceuticals Ltd. at an exercise price of $0.4359 per share.

5. Received in the merger between the issuer and Immune Pharmaceuticals Ltd. in exchange for options to acquire 20,000 ordinary shares of Immune Pharmaceuticals Ltd. at an exercise price of $0.6122 per share.

	Daniel G. Teper	08/27/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.